Understanding how SLC22A24 affects drug absorption and metabolism
Characterizing the physiological and pharmacological roles of SLC22A24
This study is looking at a protein called SLC22A24 to see how it helps the body absorb medications and hormones, which could lead to better ways to use these treatments safely and effectively for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10807063 on NIH RePORTER |
What this research studies
This research investigates the SLC22A24 protein, which is involved in the transport of various substances in the body, including drugs and hormones. By using advanced techniques such as cell line studies and isotopic assays, the research aims to identify the specific roles of SLC22A24 in drug absorption and the metabolism of steroid compounds. The findings could help clarify how this protein influences the effectiveness and safety of medications, potentially leading to better therapeutic strategies. Patients may benefit from a deeper understanding of how their medications are processed in the body.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are taking medications that may be affected by the SLC22A24 transporter or those with conditions related to steroid metabolism.
Not a fit: Patients who are not on any medications or do not have conditions related to steroid metabolism may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved drug therapies and personalized medicine approaches for patients based on their unique metabolic profiles.
How similar studies have performed: Previous research has successfully characterized other solute carrier transporters, suggesting that this approach may yield valuable insights into SLC22A24 as well.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Giacomini, Kathleen M — University of California, San Francisco
- Study coordinator: Giacomini, Kathleen M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.